Our Approach
We envision a future where every cancer patient receives tailored therapy that improves outcomes and enhances quality of life. By harnessing the power of advanced molecular analysis and collaboration with leading clinical institutions, we aim to establish a new standard in cancer treatment.
Our approach contains of three pillars. The complete workflow for capturing circulating tumor cells, molecular characterization of those cells (DNA, RNA, proteins), and translating these findings into personalized therapeutic options is now consolidated under one roof. This end-to-end workflow for isolation and molecular characterization of CTCs is called TzuPlus.
Our Pillars
We have developed technology that enable us to extract a few tumor cells from billions of white blood cells. The technology is a new approach for separating cancer cells from white blood cells obtained through leukapheresis. A typical leukapheresis product contains billions of white blood cells and only a few dozen to hundreds of circulating tumor cells. The Fetch technology enables rapid and effective enrichment of tumor cells for further analysis.
CTC enrichment & isolation
After we have collected the CTCs, we process the DNA and RNA of small amounts of CTCs to create the Circulating Cancer Catalogue (CCC), providing in-depth genomic and transcriptomic information for individual patients.
DNA & RNA Sequencing
We are developing software to routinely analyze all molecular data from tumor cells, such as identifying which drug targets are present within a tumor. We generate a report for each patient/tumor based on our measurements.
Bioinformatics
Our TzuPlus technology can be used to obtain deep molecular information for any patient with cancer. The platform will be the basis for development of the next-generation of cancer therapy tailored to the molecular characteristics of each patients tumor cells.
